M&A Deal Summary

Arrevus Acquires Melinta Therapeutics - Fusidic Acid

On February 5, 2019, Arrevus acquired life science company Melinta Therapeutics - Fusidic Acid from Melinta Therapeutics

Acquisition Highlights
  • This is Arrevus’ 1st transaction in the Life Science sector.
  • This is Arrevus’ 1st transaction in the United States.
  • This is Arrevus’ 1st transaction in Connecticut.

M&A Deal Summary
Date 2019-02-05
Target Melinta Therapeutics - Fusidic Acid
Sector Life Science
Buyer(s) Arrevus
Sellers(s) Melinta Therapeutics
Deal Type Divestiture

Target

Melinta Therapeutics - Fusidic Acid

New Haven, Connecticut, United States
Melinta Therapeutics, Inc. - Fusidic Acid is an antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Arrevus

Durham, North Carolina, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. The company is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). Arrevus was formed in 2015 and is based in Durham, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1

Seller(S) 1

SELLER

Melinta Therapeutics

New Haven, Connecticut, United States
Category Company
Sector Life Science
DESCRIPTION

Melinta Therapeutics is a molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-29 The Medicines Company - Infectious Disease Business

Parsippany, New Jersey, United States

The Medicines Company - Infectious Disease Business includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline).

Buy $270M
Mergr

Product

Company

Legal